https://www.selleckchem.com/pr....oducts/nexturastat-a
Six predictive scores were developed and validated to predict incident HCC during ETV/TDF therapy in CHB patients. Common scoring variables included age, sex, cirrhosis (fibrosis grade) and hepatic function. Conflicting results were reported in 7 individual studies and 2 meta-analyses that compared ETV vs. TDF. CONCLUSIONS The residual risk of HCC remains during ETV/TDF treatment in CHB patients with cirrhosis, but declines over time. Risk stratification is attainable by validated predictive scores. This article is protected by co
Like
Comment
Share
